APR 12, 2017 9:00 AM PDT

Keynote Presentation - Assessing Risk in Cervical Cancer Screening Management: The Role of HPV Genotyping

Sponsored by: Roche Diagnostics
Speaker
  • Consultant Senior Director, Clinical Research
    Biography
      Catherine Behrens did her PhD research at University of California San Francisco and attended medical school at Stanford University. She completed a Residency in Obstetrics and Gynecology, also at Stanford. Dr. Behrens was in clinical practice for over 20 years and maintains board certification from the American College of Obstetricians and Gynecologists. Dr. Behrens returned to research in the women's health field, initially at Genomic Health and then serving as Senior Director for Clinical Research at Roche Molecular Diagnostics from 2009 until 2015. During her tenure at Roche, Dr. Behrens was the clinical lead for the ATHENA study and a number of additional registrational trials. She currently serves as a consultant in women's health care.

    Abstract

    Screening for cervical cancer represents one of the greatest successes achieved in disease prevention. Cytology has been central to cervical cancer screening programs for over 50 years and has contributed to the 70% decline in rates of cervical cancer in the developed world.3 By the 1990’s, HPV was recognized as a single, necessary cause of cancer of the cervix that was detected in 99.7% of cases of cervical cancer.4 Therefore, tests that detect infection with these high-risk HPV genotypes are now being used increasingly in cervical cancer screening programs.  The 2007 Consensus Guidelines for the Management of Women with Abnormal Cervical Cancer Screening Tests6 recognized the utility of using a combination of cervical cytology, tests for HPV, and genotype-specific HPV testing for women undergoing screening for cervical cancer. These guidelines were subsequently revised and now recommend the combination of cytology and HR HPV testing (cotesting) as the preferred method of screening in women ≥30 years, with HPV 16/18 genotype–specific testing an added option to triage women with negative cytology to colposcopy.7 Most recently, the FDA approved the use of the cobas HPV Test as the first-line primary screen and interim guidance for this screening strategy has been issued and supported by 3 professional societies.

     

    The numerous guideline changes have presented challenges to both laboratories and clinicians. For laboratories, decisions needed to be made regarding which HPV assay to run and how to re-organize resources and workflow to accommodate changing guidelines. For clinicians, choosing the optimal screening strategy and then understanding how to manage the results has become a difficult task.

     

    Today we will try to simplify approaches to cervical cancer screening and management by reviewing the role of HPV genotyping in risk management. Cytology and HPV genotyping results can be used to quantify risks so that we can identify women at the highest risk of having or developing cervical disease and conversely, to identify women at the lowest risk. By utilizing this risk assessment approach, laboratorians and clinicians will better be able to choose the most efficient screening methodology and also more easily manage results that are often confounding and confusing.


    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    APR 21, 2021 10:00 AM PDT
    C.E. CREDITS
    APR 21, 2021 10:00 AM PDT
    Date: April 21, 2021 Time: 10:00am (PDT), 1:00pm (EDT) Serological testing for SARS-CoV-2 has been steadily adopted into clinical practice over the course of this pandemic. In this webinar,...
    APR 01, 2021 8:00 AM PDT
    C.E. CREDITS
    APR 01, 2021 8:00 AM PDT
    Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
    APR 20, 2021 11:00 AM PDT
    C.E. CREDITS
    APR 20, 2021 11:00 AM PDT
    Date: April 20, 2021 Time: 11:00am (PST), 2:00pm (EST) Identification and confirmation of microbial isolates is crucial in the analysis workflow, providing decision-makers the information...
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
    MAY 18, 2021 8:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    MAY 18, 2021 8:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: May 18, 2021 Time: 8:00am (PST) The global pandemic has caused an increased focus and scrutiny on molecular diagnostic assay development, resulting in a need for assays that provide qu...
    APR 12, 2017 9:00 AM PDT

    Keynote Presentation - Assessing Risk in Cervical Cancer Screening Management: The Role of HPV Genotyping

    Sponsored by: Roche Diagnostics

    Specialty

    Molecular Diagnostics

    Laboratory Testing

    Dna

    Biology

    Genomics

    Clinical Diagnostics

    Therapy

    Behavior

    Pcr/rt-Pcr/real-Time Pcr

    Behavior Sciences

    Molecular Genetics

    Molecular Biology

    Infectious Disease

    Clinical Medicine

    Cancer

    Geography

    North America80%

    South America20%

    Registration Source

    Website Visitors100%

    Job Title

    Medical Laboratory Technician50%

    Executive25%

    Facility/Department Manager25%

    Organization

    Hospital20%

    Pharmaceutical Company20%

    Clinical Laboratory20%

    Animal Hospital20%

    Academic Institution20%


    Show Resources
    Loading Comments...
    Show Resources
    Attendees
    • See more